📰 Label Study News
Page 2 - Label Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Label Study. Real-time updates on events, politics, business and more.
February 7, 2023
07.02.2023 - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update ...
November 3, 2022
03.11.2022 - Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January Presentations at upcoming scientific conferences highlight company’s novel approach to treating complement-mediated ...
October 7, 2022
/PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from studies of Endo Aesthetics Qwo® (collagenase clostridium...
October 7, 2022
DUBLIN, Oct. 7, 2022 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from studies of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes), an FDA-approved
September 15, 2022
Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD)
September 13, 2022
FAIRFIELD (dpa-AFX) - GE Healthcare, the healthcare business of conglomerate General Electric Co. (GE), along with Lantheus Holdings Inc. (LNTH) announced Tuesday that the recent Phase III clinical
January 21, 2022
First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC Two...
October 25, 2021
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today presented a poster on Part 1, the open-label portion, of the study of SLS-002 at the IASRAFSP International Summit on Suicide Research Virtual Conference. The poster titled A Phase 2 Open Label Study of Efficacy, Safety, and Tolerability of SLS-002 ...
October 1, 2021
/PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central...
October 1, 2021
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has been selected to present a poster on SLS-002 at the IASRAFSP International Summit on Suicide Research Virtual Conference, October 24-27 th 2021. Seelos will present the following in Poster Session 1 on Monday, October 25 th ...